Results 231 to 240 of about 404,841 (308)
Correction to "Assessment of Chronic Rhinosinusitis With Nasal Polyps: Development of the Nasal Polyp Patient Assessment Scoring Sheet Tool". [PDF]
Laryngoscope Investig Otolaryngoleuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Archives of Allergy and Immunology, 2021
Introduction: Compared with the placebo, biologics are beneficial in reducing nasal polyp mass and safe in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, there lacks a head-to-head randomized trial comparing biologics. We aimed
Qingwu Wu +8 more
semanticscholar +1 more source
Introduction: Compared with the placebo, biologics are beneficial in reducing nasal polyp mass and safe in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, there lacks a head-to-head randomized trial comparing biologics. We aimed
Qingwu Wu +8 more
semanticscholar +1 more source
Clinical and Experimental Allergy, 2021
Chronic rhinosinusitis with nasal polyps (CRSwNP) can be a severe and debilitating disease associated with significant morbidity, loss of smell, sinus pressure and asthma exacerbations.
J. Tversky, A. Lane, A. Azar
semanticscholar +1 more source
Chronic rhinosinusitis with nasal polyps (CRSwNP) can be a severe and debilitating disease associated with significant morbidity, loss of smell, sinus pressure and asthma exacerbations.
J. Tversky, A. Lane, A. Azar
semanticscholar +1 more source
Science immunology, 2021
Transcriptional profiling pinpoints the heterogeneity of T helper cells in human nasal polyps at the clonal level. Who nose the T cell subsets in nasal polyps?
Junjie Ma +7 more
semanticscholar +1 more source
Transcriptional profiling pinpoints the heterogeneity of T helper cells in human nasal polyps at the clonal level. Who nose the T cell subsets in nasal polyps?
Junjie Ma +7 more
semanticscholar +1 more source
International Forum of Allergy and Rhinology, 2021
Dupilumab is a novel monoclonal antibody that recently received US Food and Drug Administration approval for the treatment of chronic rhinosinusitis with nasal polyps.
A. Parasher +5 more
semanticscholar +1 more source
Dupilumab is a novel monoclonal antibody that recently received US Food and Drug Administration approval for the treatment of chronic rhinosinusitis with nasal polyps.
A. Parasher +5 more
semanticscholar +1 more source
The Laryngoscope, 2020
Both endoscopic sinus surgery (ESS) and biologic therapies have shown effectiveness for medically‐refractory chronic rhinosinusitis with nasal polyps (CRSwNP) without severe asthma. The objective was to evaluate cost‐effectiveness of dupilumab versus ESS
George A Scangas +6 more
semanticscholar +1 more source
Both endoscopic sinus surgery (ESS) and biologic therapies have shown effectiveness for medically‐refractory chronic rhinosinusitis with nasal polyps (CRSwNP) without severe asthma. The objective was to evaluate cost‐effectiveness of dupilumab versus ESS
George A Scangas +6 more
semanticscholar +1 more source
A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis
Nature Genetics, 2019Stefania Benonisdottir +2 more
exaly +2 more sources
International Forum of Allergy and Rhinology, 2021
Central compartment atopic disease (CCAD) is a variant of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) characterized by polypoid changes of the superior nasal septum, middle (MT), and/or superior turbinates (ST).
Andrew J. Steehler +3 more
semanticscholar +1 more source
Central compartment atopic disease (CCAD) is a variant of chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) characterized by polypoid changes of the superior nasal septum, middle (MT), and/or superior turbinates (ST).
Andrew J. Steehler +3 more
semanticscholar +1 more source
International Forum of Allergy and Rhinology, 2021
Outside of SINUS‐24 (A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps) and SINUS‐52 (Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps), there are limited data on the efficacy of dupilumab in patients ...
Harish Dharmarajan +3 more
semanticscholar +1 more source
Outside of SINUS‐24 (A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps) and SINUS‐52 (Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps), there are limited data on the efficacy of dupilumab in patients ...
Harish Dharmarajan +3 more
semanticscholar +1 more source